Global /Australia /Healthcare /Drug Manufacturers - Specialty & Generic /EVE
chevron_leftBack
EVE Health Group Ltd. logo

EVE Health Group Ltd.

EVE
ASX: EVE Delayed
0.0300AUD -3.2%
0.0214 USD
As of 5 June 2026, EVE Health Group Ltd. has a market cap of $7.73M USD, ranking #42597 globally and #1419 in Australia. It ranks #3766 in the Healthcare sector, and #261 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
42597
Country Rank
1419
Sector Rank
3766
Industry Rank
261
Key Stats
Market Cap
$7.73MUSD
10.84M AUD
Enterprise Value
$7.1MUSD
9.95M AUD
Revenue (TTM)
$971.42KUSD
1.36M AUD
EBITDA (TTM)
-$1.18MUSD
-1.65M AUD
Net Income (TTM)
-$1.16MUSD
-1.62M AUD
EBITDA Margin
-121%
Profit Margin
-119%
PS Ratio
8.0
PB Ratio
2.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Gregory Fry open_in_new
Employees
3
Founded
2003
Website
evehealthgroup.com.au open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-3.2% 6.9% 41% 55% 19% -23%

News

Loading...

Markets

Exchange Ticker Price
Australian Securities Exchange
MIC: XASX
PRIMARY
EVE
EVE Health Group Ltd
ISIN: AU000000EVE3
Shares Out.:
352.327M1 Shares Float: 324.6M2
TV:
SA:
YF:
GF:
BA:
EVE
MS:
0.0300 AUD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About EVE Health Group Ltd.

EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was formerly known as EVE Investments Limited. EVE Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (Australia)
Name
Market Cap diff.
PE
$1.11B
1.55B AUD
14K%
52.7
$123.03M
172.39M AUD
1K%
-
$114.37M
160.26M AUD
1K%
18.1
$100.03M
140.17M AUD
1K%
14.1
$56.42M
79.06M AUD
630%
-
BNIGF
$49.41M
539%
-
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
PE
$37.66B
108.92B ILS
487K%
24.2
$29.56B
382K%
-
$15.86B
107.34B CNY
205K%
16.0
CIPLA
$11.12B
1.06T INR
144K%
23.4
LUPIN
$11.0B
1.05T INR
142K%
22.7
$9.1B
61.6B CNY
118K%
80.6
chevron_leftBack